Home/Investors/Cormorant Asset Management

Cormorant Asset Management

Biotech Investor · 2 portfolio companies

Portfolio

2

Combined Value

$1.9B

Focus Areas

6

Top Stage

Phase 3

Investment Focus

Oncology Women's Health Breast Cancer Neurology Rare Genetic Diseases Neuromuscular

Portfolio Companies

Company	Stage	Valuation	Focus
Olema Pharmaceuticals	Phase 3	$1.2B	Oncology, Women's Health
Design Therapeutics	Phase 1	$635.8M	Neurology, Rare Genetic Diseases

Frequent Co-Investors

BVF Partners1 shared RA Capital Management1 shared Logos Capital1 shared Venrock Healthcare Capital Partners1 shared New Enterprise Associates (NEA)1 shared SR One (GSK's venture arm)1 shared Quan Capital1 shared Boxer Capital1 shared